Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 days ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 15 days ago STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 2 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 3 months ago STAT+: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more - 3 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer - 6 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 8 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 8 months ago STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 9 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 9 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 9 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal - 10 months ago STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness - 10 months ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - 10 months ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - 10 months ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - 10 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - 11 months ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - 11 months ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - 11 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - 11 months ago STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer - 11 months ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - 12 months ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - 12 months ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - 12 months ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - 12 months ago
2	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Lilly has more positive data on its weekly insulin - 14 days ago FDA chastens pet companies over antibiotics - 9 months ago Johnson & Johnson bets heavy on AI-driven drug discovery - 10 months ago Johnson & Johnson antiviral pill for dengue shows early efficacy - 11 months ago
3	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback - about 1 month ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 2 months ago STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest - 7 months ago STAT+: Pfizer is about to make a big push in cancer. Will investors listen? - 7 months ago
4	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 2 months ago STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial - 10 months ago
5	Cory Renauer Motley Fool Writes on healthcare, fintech. Michigan, USA Investinghealthcarefintech	Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip? - 2 months ago
6	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll - 3 months ago GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that. - 6 months ago
7	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 4 months ago COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter - 6 months ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Pfizer’s plot to win the RSV vaccine race - 5 months ago Is it time to worry about Moderna? - 9 months ago STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup - 10 months ago Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro - 11 months ago
9	Keith Speights Motley Fool Investor, author, Motley Fool contributor. investingwriting	Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market? - 6 months ago Why Pfizer Stock Is Sinking Today - 9 months ago Why Pfizer Stock Is Sinking Today - 10 months ago
10	https://www.facebook.com/ichiro51 GeekWire Tech news and analysis. Seattle, Washington technologystartupsnews	Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition - 7 months ago

Journalists covering Pfizer